Digital Pathology Market Size, Share & Analysis Report, 2025-2034
The digital pathology market size was exhibited at USD 1.11 billion in 2024 and is projected to hit around USD 2.43 billion by 2034, growing at a CAGR of 8.1% during the forecast period 2025 to 2034.
The U.S. digital pathology market size is evaluated at USD 0.340 million in 2024 and is projected to be worth around USD 0.750 million by 2034, growing at a CAGR of 7.45% from 2025 to 2034.
North America dominated overall market in 2024 with a share of 41.0% due to increasing government initiatives leading to the development of technologically advanced pathologies, continual deployment of R&D investments, rising adoption of digital imaging, and presence of key market players in the region focusing on providing better solutions to the population. For instance, in March 2024, PathAI launched AISight, a digital pathology platform across the U.S. in 13 leading health systems, reference laboratories, medical centers, and independent pathology organizations to participate in Early Access Program. Moreover, increasing usage of digital pathology in academic research and disease diagnosis is propelling the market growth.
Asia Pacific is expected to grow at the fastest CAGR from 2025 to 2034. This growth is attributed to rapid digitalization, a rising focus on investments in the medical field, and a rising digital imaging penetration in developing economies. The region shows an increasing prevalence of cancer, which propels the need for novel treatment options, further boosting market growth. In March 2024, Qritive entered into collaboration with Corista for the integration of AI using the company’s DP3, a DICOM-compliant pathology software in digital pathology. Such initiatives help in providing better patient care, with novel treatment options, and subsequently reducing laboratory cost expenses.
| Report Coverage | Details |
| Market Size in 2025 | USD 1.20 Billion |
| Market Size by 2034 | USD 2.43 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 8.1% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product, Type, Application, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Leica Biosystems Nussloch GmbH (Danaher); Hamamatsu Photonics, Inc.; Koninklijke Philips N.V.; Olympus Corp.; F. Hoffmann-La Roche Ltd.; Mikroscan Technologies, Inc.; Inspirata, Inc.; Epredia (3DHISTECH Ltd.); Visiopharm A/S; Huron Technologies International Inc.; ContextVision AB; HANGZHOU ZHIWEI INFORMATION TECHNOLOGY CO. LTD. (MORPHOGO); West Medica Produktions- und Handels- GmbH (West Medica); aetherAI; IBEX (IBEX MEDICAL ANALYTICS); SigTuple Technologies Private Limited; Morphle Labs, Inc; Bionovation Biotech, Inc. |
The device segment held the largest share of 51.72% in 2024 and is anticipated to grow at a lucrative growth rate during the projected period. The device segment includes slide management system and scanner. The segment growth is attributed to increasing adoption of digital pathology in academic research activities with enhanced resolution. For instance, in June 2022, F. Hoffmann-La Roche Ltd. received a CE marking for its VENTANA DP 600 slide scanner, a next-generation, high-capacity slide scanner that generates high-resolution digital images of stained tissue samples to aid in cancer diagnosis and treatment planning.
The software segment is expected to register fastest growth rate from 2025 to 2034. This growth is attributed to rising number of cancer cases with key players focusing on the development of novel digital pathology systems in the industry. For instance, in August 2021, Xybion Corp. launched Pristima XD Digital Pathology, which helps in providing improved lab throughput allowing streamlining workflows. In January 2019, F. Hoffmann-La Roche Ltd. launched uPath enterprise software, for improving performance, speed, and use for digital pathology. Such innovative incorporation of integrated software helps in improving workflows.
The hospitals segment dominated the market in 2024 with a share of 37.0%. Hospitals are the most preferred healthcare setting for disease diagnosis and care. Developments in hospital laboratories are crucial to address the evolving needs of patients with more hospitals aiming to provide a wide range of services within their settings. A number of hospitals are implementing digital scanning techniques to improve patient compliance and speed diagnosis. For instance, in March 2024, Ibex (Ibex Medical Analytics) received a PathLAKE contract to provide AI-enabled solutions at 25 NHS to support cancer diagnosis.
The diagnostic labs segment is expected to grow at the fastest growth rate from 2025 to 2034 owing to increasing focus on drug development, preclinical GLP pathology, and oncology clinical trials. Moreover, increasing prevalence of cancer and the adoption of digital pathology in diagnostics labs is fueling the market growth. For instance, in January 2022, Inform Diagnostics launched FullFocus, a digital pathology viewer developed by Paige in its laboratory to use AI tools that would help in streamlining logistics and allow to achieve faster results.
The human pathology segment held the largest share of around 60.0% in 2024. The adoption of digital pathology to reduce turnaround time for disease diagnosis and enhance lab productivity is fueling segment growth. In addition, the rising prevalence of chronic diseases in humans has increased the demand for digital pathology.
Veterinary digital pathology is anticipated to experience substantial growth over the forecast period. The implementation of digital pathology in the veterinary sector is facilitated by fewer restrictions on veterinary diagnoses using virtual scanned slides. Furthermore, the proactive push for automation is driving the demand for the use of digital pathology in the veterinary field.
The academic research segment dominated the market in 2024 with a share of 45.7% and is anticipated to remain dominant from 2025 to 2034 owing to the continual research in the development of cancer therapies and high adoption of digital pathology in various research studies. A number of academic research institutes are collaborating with digital pathology providers to incorporate the technology into research activities. In November 2022, the University Medical Center Utrecht entered into a partnership with Paige for the deployment of the company’s application in clinical use and to conduct a clinical health economics study to support reimbursement and adoption of AI applications in pathology.
Disease diagnosis is anticipated to witness the fastest growth rate from 2025 to 2034 owing to increasing prevalence of chronic diseases, and increasing focus of manufacturers for the development of rapid and novel diagnostics techniques for ease in the circulation of inter and intra-departmental information. Digital adoption of technologies helps in improving and enhancing the efficiency of disease diagnosis and, hence, improving therapeutics. For instance, in April 2022, PreciseDx entered into collaboration with The Michael J. Fox Foundation for the launch of AI-enabled digital pathology technology for the diagnosis of Parkinson's disease before severe symptoms are seen in patients.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the digital pathology market
By Product
By Type
By Application
By End-use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers